

October 29, 2021

Rafael Pharmaceuticals Provides Update on Pivotal Phase 3 Clinical Trial in Patients with Metastatic Pancreatic Cancer and Interim Analysis of Pivotal Phase 3 Clinical Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia

This information is intended to notify the press release issued on October 28 (local time) by Rafael Pharmaceuticals, Inc. Please click <https://rafaelpharma.com/press-releases> for the original press release.

About the Ono and Rafael Pharmaceuticals Collaboration

In June 2019, Ono Pharmaceutical Co., Ltd. entered into a license agreement with Rafael Pharmaceuticals, Inc. to receive rights to exclusively develop and commercialize devimistat (CPI-613/ONO-7912), a cancer metabolism inhibitor, and other related compounds in Japan, South Korea, Taiwan and ASEAN countries.

About Development Status of Devimistat (ONO-7912) in Japan and South Korea

Ono has been conducting Phase 1 study for the treatment of pancreatic cancer in Japan and Rafael conducting Phase 3 study for the treatment of pancreatic cancer and acute myeloid leukemia in South Korea.

Contacts:

Ono Pharmaceutical Co., Ltd.

Corporate Communications

public_relations@ono.co.jp